A new device to help pregnant women with cervical insufficiency
A Novel Device for Cervical Insufficiency in Pregnant Women
This study is testing a new device called the Cx Device to help pregnant women with cervical insufficiency, aiming to make a common surgery safer and more effective in preventing early births.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cx Therapeutics, INC NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-11006391 on NIH RePORTER |
What this research studies
This research focuses on developing a novel medical device designed to assist pregnant women suffering from cervical insufficiency, a condition that can lead to preterm birth. The device, known as the Cx Device, aims to enhance the effectiveness of the existing surgical treatment called cervical cerclage, which involves placing a suture around the cervix to prevent premature dilation. By using a unique design with silicone plates, the device seeks to improve outcomes and reduce potential complications associated with traditional cerclage procedures. The research will involve testing the device's safety and efficacy in clinical settings to ensure it provides better support for women at risk of preterm birth.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant women diagnosed with cervical insufficiency who are at risk of preterm birth.
Not a fit: Patients who are not pregnant or those without a diagnosis of cervical insufficiency may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the rates of preterm birth and improve health outcomes for newborns and their families.
How similar studies have performed: While cervical cerclage is a well-established procedure, the Cx Device represents a novel approach that has not been tested in this specific manner before.
Where this research is happening
Lexington, United States
- Cx Therapeutics, INC — Lexington, United States (Active)
Researchers
- Principal investigator: House, Michael Douglas — Cx Therapeutics, INC
- Study coordinator: House, Michael Douglas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.